WHO ICTRP trial
PARIS-Pembrolizumab in combination with radiotherapy in locally advanced…
ISRCTN14634058 · International Standard Randomised Controlled Trial Number (ISRCTN) · Not Recruiting
Key facts
| Trial ID | ISRCTN14634058 |
|---|---|
| Public title | PARIS-Pembrolizumab in combination with radiotherapy in locally advanced non-small cell lung cancer (NSCLC) |
| Scientific title | A Phase I Study of Pembrolizumab anti PD-1 monoclonal antibody in combination with Radiotherapy in locally advanced Non-Small Cell Lung Cancer (NSCLC) |
| Primary sponsor | The Christie NHS Foundation Trust |
| Registry | International Standard Randomised Controlled Trial Number (ISRCTN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase I |
| Countries | United Kingdom |
| Conditions | Lung Cancer Cancer Cancer/ Malignant neoplasms of respiratory and intrathoracic organs |
| Interventions | Participants receive the first dose of pembrolizumab two weeks before the start of radiotherapy. Pembrolizumab is subsequently delivered every three weeks, starting on the first day of radiotherapy and are continued after completion of… |
| Registration date | Jul 19, 2017 |
| Target size | 25 |
| Secondary IDs | 2017-000444-17;34452 |
| Registry page | isrctn.com |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: